Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 16

1199TiP - Phase I trial of in situ vaccination with autologous CCL21-modified dendritic cells (CCL21-DC) combined with pembrolizumab for advanced NSCLC

Date

10 Sep 2022

Session

Poster session 16

Topics

Clinical Research;  Tumour Immunology;  Translational Research;  Multi-Disciplinary and Multi-Professional Cancer Care;  Cell-Based Therapy;  Immunotherapy;  Image-Guided Therapy

Tumour Site

Non-Small Cell Lung Cancer

Presenters

Aaron Lisberg

Citation

Annals of Oncology (2022) 33 (suppl_7): S448-S554. 10.1016/annonc/annonc1064

Authors

A.E. Lisberg, B. Liu, R. Salehi-rad, J.M. Lee, L. Tran, K. Krysan, R. Lim, C. Dumitras, Z. Jiang, F. Abtin, R. Suh, S. Genshaft, S. Oh, G.A. Fishbein, C.M. O'Higgins, D. Greenwald, J.W. Goldman, D. Elashoff, E.B. Garon, S. Dubinett

Author affiliations

  • Medicine, University of California, Los Angeles, *** - ***/US

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1199TiP

Background

Effective immunotherapy options are lacking for patients with advanced NSCLC who progress on a PD-(L)1 inhibitor and for those that EGFR or ALK positive after progression on TKI therapy. One potential approach to improve ICI efficacy is to promote cytolytic T cell infiltration into tumors. This can be accomplished via in situ vaccination with functional antigen presenting cells which can take advantage of the full repertoire of tumor antigens and convert the tumor into a lymph node-like environment promoting both local and systemic T cell activation. The chemokine CCL21 promotes co-localization of naive T cells and antigen-experienced dendritic cells (DCs) to facilitate T cell activation. Our preclinical studies and phase I trial of intratumoral (IT) administration of DC genetically modified to overexpress CCL21 (CCL21-DC) revealed augmentation of tumor antigen presentation in situ, resulting in systemic antitumor immunity. However, increased PD-L1 expression was observed following therapy in some patient tumors, suggesting that tumor-mediated impairment of T cell function may be forestalling a more robust CCL21-DC mediated antitumor response. Therefore, we are conducting a phase I trial, combining IT CCL21-DC with pembrolizumab in patients with advanced NSCLC.

Trial design

Phase I, dose-escalating, trial followed by dose expansion. Maximum of 24 patients (9-12 escalation + 12 expansion) with stage IV NSCLC will be evaluated who have tumors accessible for IT injection and are either (1) EGFR/ALK wild-type after progression on a PD-(L)1 inhibitor or (2) EGFR/ALK mutant after progression on TKI therapy. Three IT injections of autologous CCL21-DC (days 0, 21, 42) will be concurrently administered with pembrolizumab, followed by q3wk pembrolizumab. Primary objective of dose escalation is safety and determination of maximum tolerated dose (MTD) of IT CCL21-DC (5x106, 1x107, or 3x107) when combined with pembrolizumab. Primary objective of dose expansion is objective response rate at MTD. Secondary objectives include adverse event profiling and determination of drug target activity by immune monitoring studies. This trial, NCT03546361, is currently open for enrollment.

Clinical trial identification

NCT03546361.

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Merck, LUNGevity, NIH-NCI, DOD, California Institute for Regenerative Medicine (CIRM).

Disclosure

A.E. Lisberg: Financial Interests, Personal, Full or part-time Employment, Wife: Boston Scientific; Financial Interests, Personal, Stocks/Shares, Wife: Boston Scientific; Financial Interests, Institutional, Research Grant: Daiichi Sankyo, Calithera Biosciences, AstraZeneca, Dracen Pharmaceuticals, WindMIL; Non-Financial Interests, Personal, Leadership Role: Daiichi Sankyo; Non-Financial Interests, Personal, Advisory Board: Daiichi Sankyo; Financial Interests, Personal, Advisory Board: AstraZeneca, Bristol-Myers Squibb, Novocure, Pfizer, MorphoSys, Eli-Lilly, Oncocyte, Novartis, Regeneron; Financial Interests, Personal, Advisory Role: AstraZeneca, Leica Biosystems, Jazz Pharmaceuticals, Eli-Lilly, Oncocyte. J.M. Lee: Financial Interests, Personal, Advisory Board: AstraZeneca, Bristol Myers Squibb, Genentech, Novartis; Financial Interests, Personal, Advisory Role: AstraZeneca, Genentech, Novartis; Financial Interests, Personal, Research Grant: Genentech, Novartis, Merck; Financial Interests, Personal, Leadership Role: Genentech, Novartis. E.B. Garon: Financial Interests, Personal, Advisory Board: Novartis, Merck, BMS, EMD Serono, Regeneron, Sanofi, Natera, Shionogi, ABL Bio, Xilio, GSK, Boehringer Ingelheim, Eisai, Gilead, Eli Lilly, Personalis; Financial Interests, Institutional, Invited Speaker: Novartis, Merck, EMD Serono, Eli Lilly, Genetech, Iovance, Neon, Mirati, AstraZeneca, BMS, ABL Bio; Non-Financial Interests, Advisory Role, Scientific Advisory Board: Lungevity. S. Dubinett: Financial Interests, Personal, Advisory Board: EarlyDiagnostics, Johnson & Johnson Lung Cancer Initiative, LungLife AI, Inc., T-Cure Bioscience, Inc.; Financial Interests, Personal, Research Grant: Johnson & Johnson Lung Cancer Initiative, Novartis. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.